Replacement methods for toxicity prediction are often deployed: a) as part of a test battery; b) in a tiered (hierarchical) scheme; or c) in a combination of the two approaches. However, the development and validation of test batteries and tiered testing strategies is controversial -no test battery or tiered testing scheme has yet been formally validated.
This Editorial was stimulated by two recent publications. The first of these, a report by a committee of the National Academy of Sciences in the USA, 1 includes the statement: '…the committee envisions that a suite of new tests typically will be needed to replace an individual in vivo test, given that apical findings can trigger multiple mechanisms… although it is current practice to validate a single test… the new paradigm would routinely entail validation of test batteries and would use multivariate comparisons.' In the second publication, 2 while discussing the concept of validation, Thomas Hartung states that: 'at this moment we lack most of the tools to compose and to validate… testing strategies. They certainly require more substances to be tested, both to determine the proper composition of the tests and to validate the strategy. The main question… is whether we have to and can validate individual tests separately or only the overall strategy.'
Both these publications raise important issues, in view of the great interest and effort being expended by many, including myself, in devising and applying testing schemes for endpoints such as acute toxicity, reproductive toxicity, sensitisation and target organ toxicity (e.g. in large EU-funded projects such as ACuteTox, ReProtect and Sens-it-iv), 3 and for socalled intelligent testing strategies for the REACH system (the EU legislation on chemicals risk assessment, which came into force on 1 June, 2007). 4 Therefore, it is timely to consider: a) the differences between test batteries and testing strategies; b) why they are necessary; c) how they should be developed; d) whether they need to be validated; and e) how they should be validated.
Test batteries and tiered testing schemes have distinct characteristics that are important to recognise, particularly when individual component tests and criteria for validation are being considered. Test batteries comprise a group of tests that are designed to complement each other, in so much as the whole group can detect all chemicals acting via all the mechanisms thought to be involved in the toxic endpoint of interest. The tests in the battery are considered to be of equal weight in terms of providing information for making a decision about toxicity. It follows that tests in a battery can be performed in any order, or simultaneously.
In addition, each test will have a specific purpose and applicability domain (AD), for those chemicals that act via the mechanism of toxicity on which the test is based. The omission of any test would, however, compromise the overall predictivity of the battery. The essential requirement is that the AD of the overall test battery covers all possible mechanisms of action of the different agents that can cause the relevant toxicity. In addition, the ideal test battery would have the minimum number of tests required to cover all the modes of action that are responsible for causing and alleviating (e.g. leading to recovery from) the toxicity being predicted. This requirement could be fulfilled most simply by selecting tests that complement each other, and that are not based on common mechanisms of action (i.e. that do not detect the same spectrum of chemicals). 5 A tiered testing scheme differs from the above, in that it is usually composed of a sequence of tests that increase in complexity, with the simplest and most straightforward approaches (usually not animal-based) being the first to be undertaken, culminating in more-complex (usually animal-based) methods. 6 Tiered testing schemes are ideal for screening purposes, and are widely used as such during the early stages of pharmaceutical development, when large numbers of candidate chemicals can be assessed rapidly and cheaply, in order to sieve out any with contra-indications as early as possible, before those that remain are tested by using the more-complex methods.
The component tests in tiered schemes are not considered to be of equal weight, and consequently are not undertaken simultaneously, but sequentially. Whether to undertake a test in the strategy is usually determined by the result obtained in the test immediately preceding it. When essentially different types of approaches are involved (e.g. the use of pre-existing data, in silico predictions of pharmacokinetics and toxicity, in vitro tests, and in vivo tests), a tiered testing scheme is often referred to as an integrated testing strategy. Such strategies can also involve a number of decision points, at which further testing can be avoided. 4, 7 In practice, many Editorial Developing, Validating and Using Test Batteries and Tiered (Hierarchical) Testing Schemes tiered testing schemes comprise some individual tiers which consist of a number of tests of equal weight (i.e. test batteries). When using a tiered strategy, the outcome is not necessarily dependent on all the tests having been conducted, since it is possible to end further testing at each stage of the tier, depending on the results obtained so far and the purpose of the testing (e.g. whether for classification and labelling or for quantitative risk assessment).
The use of integrated testing schemes contributes to the Three Rs, since scientifically advanced, replacement methods are used initially for all test substances. Then only those chemicals that pass the earlier tier are subjected to further testing, which usually involves more time-consuming and more expensive in vivo methods, the use of which is minimised. Thus, as one progresses down the tiered testing scheme, fewer and fewer chemicals are tested. In addition, there is a greater chance that any in vivo testing will be conducted to confirm lack of toxicity, rather than establishing it, thereby minimising any pain and suffering caused to the animals concerned. As with test batteries, each of the component methods of a tiered testing scheme will have its own purpose and AD, and the overall scheme will also have a purpose and AD, determined by the characteristics of the individual methods it contains.
Selecting tests for inclusion in a tiered testing scheme is more complicated than it is for testing batteries. It is, of course, necessary to ensure that the scheme includes tests that, when combined, are collectively sensitive to chemicals that act by all the different modes of action that are involved in causing the toxicity of interest. However, the selection of tests will also be influenced by other factors, including, in particular, the use to which the scheme will be put. Thus, if the purpose is for screening large numbers of candidate chemicals, at an early stage of the development of a product, then low cost and ease of use of a test are more important than its sensitivity (i.e. its ability to correctly predict toxicity). This is because the loss of some chemicals because of false-positive results can be more readily tolerated than is the case when there are a smaller number of candidate chemicals. Where the circumstances demand that large numbers of chemicals must be assessed, e.g. for compliance with the REACH system, sensitivity becomes more important, since there is a greater need to reduce the incidence of false-positive results.
For methods undertaken further down a tiered testing strategy, cost and rapidity assume decreasing importance the later they are used, while specificity (ability to correctly predict non-toxicity) becomes a more important property of a method, due to an increasing requirement, when progressing through the test strategy, to minimise the incidence of false-negative results (as was also acknowledged in the NAS report 1 ). The simplest way to ensure high sensitivity early on is to use a test that models a critical first stage in the mechanistic pathway responsible for the toxicity being investigated (e.g. binding to the receptor responsible for initiating release of the first cytokine in the inflammatory cascade). Greater specificity at later stages can be introduced by using tests that model processes that modulate toxicity (e.g. those which lead to recovery).
There is also a need to design tiered testing schemes which avoid the use of animals as far as possible, and for as long as possible. If the use of animals is unavoidable, then a scheme should give preference to those tests that use the least severe and least invasive procedures and require the smallest number of animals, for both financial and welfare reasons. While it is usual for in vivo tests to be the cheapest and most rapid assays, this is not always the case, and there could be a need to develop new in vitro methods to overcome this problem (e.g. avoiding the use of the bone-marrow micronucleus test by replacing the mammalian cytogenetics assay with an in vitro micronucleus test 8 ).
Thus, the procedure for the selection of tests for inclusion in tiered testing strategies should involve a consideration of: a) the purpose of the testing; b) the need to achieve an appropriate balance between test sensitivity and specificity; and c) the Three Rs (Replacement, Reduction and Refinement). Since these parameters have complex interactions, it would seem necessary to approach test selection on a case-by-case basis, despite a recent attempt by Hansson and Rudén 9 to define a strategy involving precise algorithms for constructing tiered testing schemes, based on standard decision theory.
Ideally, test batteries and tiered testing schemes should be validated. 10 However, the criteria for such validation procedures (e.g. as published by the OECD and ICCVAM) are much less well-defined than are those for validating most individual test methods. To contribute to this debate, I list the following criteria for validating test batteries and tiered testing schemes:
1. each of the component methods must previously have been individually validated in a study that satisfies the internationally-accepted criteria for validation;
2. a clear purpose and AD for the test battery or tiered testing scheme should be identified;
3. the purpose and AD should reflect the purposes and ADs for all the component tests in the test battery or tiered testing scheme;
4. the test battery or tiered testing scheme should be validated against a set of chemicals which cover the whole of the AD, so as to allow validation for its intended purpose to be properly assessed;
5. the set of chemicals used for validation should comprise a subset of each of the sets of chemicals that were used in the validation of all the component tests in the test battery or tiered testing scheme, and which are representative of the ADs of the individual methods;
6. the set of chemicals should be chosen so as to allow the performance of a tiered decision-tree testing scheme to be assessed from toxicity predictions based on data obtained at each decision point (e.g. chemicals with well-defined hazard labelling and classification, and chemicals with well-defined NOAELs for quantitative risk assessment).
In principle, there is no reason why the above criteria could not be applied immediately to validating test batteries and tiered testing schemes. It should not always be necessary that such validation should require the generation of new test data, since it ought to be possible to undertake validation retrospectively in many cases. 11 However, in practice, validating batteries and tiered testing schemes is exacerbated, since the validation of certain individual methods (e.g. in silico prediction approaches, particularly [Q]SAR modelling and expert systems) remains controversial. 12, 13 In conclusion, and returning to the two quotations as the start of this editorial, firstly, it is true that there will be an increased emphasis on test batteries and tiered testing schemes and their validation. However, this is not a new phenomenon, as there has been great interest in this area for several decades, as explained above. Thus, the statement made in the NAS report 1 is hardly compatible with its title (Toxicity Testing in the Twenty-first Century: A Vision and a Strategy)! Secondly, yes we do have the tools to validate test batteries and tiered testing schemes, but this cannot be achieved unless each component method has itself already been validated. However, their development and use should not necessarily be precluded by lack of validation, but should, particularly in the case of tiered testing schemes, depend on the number and types of methods that have been individually validated in the battery or scheme, and the purpose for which these methods are being used. Thus, where the purpose is for quantitative risk assessment, e.g. to define a NOAEL, it is crucial that the individual methods have already been formally validated. On the other hand, where a positive effect is acceptable for hazard classification, it might not be necessary for a particular test to have been formally validated. 14 However, it is most important to clearly identify the validation status of all the component methods, as we have done for our proposed integrated decision-tree testing strategies for REACH. 4 Lastly, it is recognised that the use of non-validated test batteries and tiered testing schemes represents a, hopefully temporary, compromise. The ideal situation would be for them to be formally validated according to internationally-agreed criteria, but this will first require reaching agreement on how to validate all types of the individual methods of which they are composed. Let us hope that this can be achieved in the not too distant future. 
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